You are here
Continuous Manufacturing Market
Growing at an annualized rate of over 15%, the continuous manufacturing market is estimated to be worth around USD 2 Billion by 2030, claims Roots Analysis
Compared to batch production methods, continuous manufacturing is not only more time-efficient, but is also associated with reduced energy needs, lower footprint and includes provisions to trace process-related errors and inefficiencies
Roots Analysis has announced the addition of “Continuous Manufacturing Market (Small Molecules and Biologics), 2020-2030” report to its list of offerings.
The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks. In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated. In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing.
To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link
Key Market Insights
Around 65 companies claim to have expertise in continuous manufacturing of small molecule / biologic drugs
The continuous manufacturing market landscape is dominated by well-established players (founded before 1990), which represent more than 50% of the total number of stakeholders. Amongst these, close to 55% players are headquartered in Europe, followed by those based in North America (36%).
Close to 45 partnerships were inked between 2013 and 2019
More than 55% of such agreements were focused on technology improvements and research. Further, 58% of the recent partnerships were established for drug product manufacturing, while the remaining were focused on the production of API / intermediate.
Nearly 55 expansion initiatives were undertaken in the period 2013-2020 (till January)
Most such projects (55%) were reported to be focused on establishment of a new facility / plant, followed by those carried out for incorporating continuous manufacturing technologies (28%) into the existing facilities of different companies. It is worth mentioning that more than 45% of the total number of expansions captured in the report, were observed to have been carried out in Europe.
Around 165 grants were awarded to support ongoing R&D activities in continuous manufacturing, between 2014 and 2019
Collectively, the capital amount awarded to support R&D in this field was estimated to be worth USD 69.7 million. It is worth noting that 35 grants were awarded in 2019 alone. A significant proportion of grants identified in the report (22%) were awarded to the Illinois Institute of Technology, followed by those awarded to Purdue University (12%).
To request a sample copy / brochure of this report, please visit this link
Key Questions Answered
- Who are the key players engaged in continuous manufacturing of small molecules and biologics?
- What is the installed, global capacity for continuous manufacturing?
- What are the key growth drivers within this domain?
- What are the various paths to evolution within this industry?
- Who are the other key stakeholders (modular facility providers and technology / equipment developers) in this domain?
- How is the current and future market opportunity likely to be distributed across key market segments?
The USD 1.9 billion (by 2030) financial opportunity within the continuous manufacturing market has been analyzed across the following segments:
- Purpose of Manufacturing
- Contract service
- Scale of Operation
- Preclinical / Clinical
- Type of Continuous Manufacturing related Service
- API Manufacturing
- End Product manufacturing
- Type of Drug Molecule
- Small Molecule
- Type of dosage form
- Key Geographical Regions
- North America
- Asia Pacific
Street name: A430, 4th Floor, Bestech Business Towers, Sector 66,
Pin Code: 160059
Contact Number: +14158003415
We provide market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis covering the following parameters:
Research and development
Existing market landscape
Future Commercial potential
Regional growth drivers
Risks and opportunities
We specialise in analysing areas which have lacked quality research so far or require more focussed understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.